Omnicell Inc
$ 38.18
-6.17%
10 Jun - close price
- Market Cap 1,774,132,000 USD
- Current Price $ 38.18
- High / Low $ 40.55 / 38.13
- Stock P/E 88.66
- Book Value 27.36
- EPS 0.44
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.02 %
- 52 Week High 55.00
- 52 Week Low 26.84
About
Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.
Analyst Target Price
$61.29
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-02-05 | 2025-10-30 | 2025-07-31 | 2025-05-06 | 2025-02-06 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-08 | 2023-11-02 | 2023-08-01 |
| Reported EPS | 0.55 | 0.4 | 0.51 | 0.45 | 0.26 | 0.6 | 0.56 | 0.51 | 0.03 | 0.33 | 0.62 | 0.57 |
| Estimated EPS | 0.33 | 0.5 | 0.36 | 0.27 | 0.2 | 0.58 | 0.42 | 0.14 | -0.09 | 0.15 | 0.48 | 0.28 |
| Surprise | 0.22 | -0.1 | 0.15 | 0.18 | 0.06 | 0.02 | 0.14 | 0.37 | 0.12 | 0.18 | 0.14 | 0.29 |
| Surprise Percentage | 66.6667% | -20% | 41.6667% | 66.6667% | 30% | 3.4483% | 33.3333% | 264.2857% | 133.3333% | 120% | 29.1667% | 103.5714% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMCL
2026-06-11 15:12:00
CDO Magazine provides a weekly overview of significant executive appointments and leadership transitions within the global data, AI, and analytics ecosystem. This edition highlights key leadership changes at Mars Snacking, Omnicell, and TD Bank Group, among others, focusing on how these roles support digital transformation and AI strategy. The featured moves include critical positions such as Chief Information Security Officer, SVP of Data & AI, and Global Head of Data, Analytics & AI Governance & Strategy.
2026-06-08 16:10:43
This article announces that Omnicell (NASDAQ: OMCL) is expected to report its financial results for the first quarter of fiscal year 2026 pre-market on April 28. Analysts project the company will post earnings of $0.09 per share, a significant decline from $0.51 per share in the same period last year. Revenue is estimated to be $237.95 million.
2026-06-08 13:09:23
Omnicell has appointed Dan Mandoli as senior vice president and general manager of Specialty Pharmacy Services, leveraging his 30 years of experience to expand the company's specialty pharmacy and 340B services. This strategic hire aims to enhance Omnicell's offerings for health systems navigating complex medication management and reimbursement, reinforcing the company's focus on specialty pharmacy as a key growth driver. Mandoli's background includes leadership roles at Altruix, Elevance Health, McKinsey & Company, and Express Scripts, where he focused on scaling specialty pharmacy businesses and optimizing operations.
2026-06-08 13:09:23
Omnicell, Inc. has appointed Dan Mandoli as Senior Vice President and General Manager of Specialty Pharmacy Services, leveraging his 30 years of experience in pharmacy operations. This strategic hire is expected to drive growth in Omnicell's Specialty Pharmacy and 340B businesses, which are considered key for delivering value to health systems. The company recently reported strong Q1 2026 results and has a perfect Piotroski Score, indicating strong financial health.
2026-06-08 12:10:43
Omnicell, Inc. has appointed Dan Mandoli as Senior Vice President and General Manager, Specialty Pharmacy Services. Mandoli, a veteran healthcare executive with over 30 years of experience, will oversee the Company's Specialty Pharmacy and 340B businesses, which are expected to be key growth drivers for Omnicell. His expertise in building and scaling specialty pharmacy operations is anticipated to enhance Omnicell's value proposition for customers and support its long-term growth strategy.
2026-06-08 12:09:23
Omnicell, a healthcare technology provider, has appointed Dan Mandoli as Senior Vice President and General Manager of its Specialty Pharmacy Services business. Mandoli brings over 30 years of experience in pharmacy operations and specialty pharmacy services, having held leadership roles at Alteryx, Elevance Health, and Express Scripts. His expertise is expected to be instrumental in driving the growth and scaling of Omnicell's Specialty Pharmacy and 340B businesses, which are considered key growth drivers for the company.
